Cancer Family
B-Cell Malignant Neoplasm
CI-CAN-00000070Explore in graph →
Hematologic2,083 active trials46 approved drugs301 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000070Explore in graph →
Clinical trials
7,466 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,167)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06479954 | Non Interventional Study to Investigate the Safety and Effectiveness in Patients With Relapsed and Refractory Multiple Myeloma Treated With Elranatamab Under the Actual Use. | active not recruiting | — | 1 | PfizerINDUSTRY | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05971251 | Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia | active not recruiting | Phase 1 | 24 | University of Alabama at BirminghamOTHER | 1 | Oct 1, 2025 |
| clinicaltrials |
| NCT03327597 | Iceland Screens, Treats or Prevents Multiple Myeloma(iStopMM) | active not recruiting | N/A | 80,761 | University of IcelandOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07199855 | Blinatumomab Combined With Venetoclax as Maintenance Therapy After Allo-HSCT in High-risk Ph Negative Acute B-cell Lymphoblastic Leukemia | active not recruiting | Phase 2 | 24 | Zhejiang UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT03147885 | Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 43 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT04479267 | Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma | active not recruiting | Phase 2 | 8 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT05192486 | A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL) | active not recruiting | Phase 1 / Phase 2 | 12 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05485753 | A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) | active not recruiting | Phase 1 / Phase 2 | 7 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05621096 | Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 33 | University of NebraskaOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT04697940 | Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL | active not recruiting | Phase 1 / Phase 2 | 33 | Han weidongOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT05823571 | Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients | active not recruiting | Phase 1 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06381141 | A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma | active not recruiting | Phase 1 | 30 | Cullinan Therapeutics Inc.INDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT04447716 | An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment | active not recruiting | Phase 1 | 4 | Thomas Jefferson UniversityOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT05871008 | Integrated Actionable Aging Assessment for Cancer Patients Pilot | active not recruiting | N/A | 35 | University of Colorado, DenverOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT01863550 | Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma | active not recruiting | Phase 3 | 1,087 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Sep 8, 2025 | clinicaltrials |
| NCT05673083 | Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma | active not recruiting | — | 200 | All4CureINDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07154537 | Pneumococcal Conjugated Vaccine 13 (PCV13) for Patients With Multiple Myeloma (MM) | active not recruiting | Phase 4 | 101 | National Taiwan University HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT04501939 | Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax(Venetoclax) | active not recruiting | Phase 2 | 5 | University of California, San DiegoOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT05788081 | Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab.(TOP-FLOR) | active not recruiting | Phase 2 | 40 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT03314181 | A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 2 | 156 | AbbVieINDUSTRY | 7 | Aug 14, 2025 | clinicaltrials |
| NCT05308654 | A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets | active not recruiting | Phase 1 | 34 | AbbVieINDUSTRY | 4 | Aug 14, 2025 | clinicaltrials |
| NCT02157324 | Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia | active not recruiting | Phase 1 | 12 | Acerta Pharma BVINDUSTRY | 1 | Aug 13, 2025 | clinicaltrials |
| NCT02734771 | A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)(BV mini CHP) | active not recruiting | Phase 2 | 24 | Patrick ReaganOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT03314636 | Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.(CONPET) | active not recruiting | Phase 2 | 53 | Oslo University HospitalOTHER | 3 | Aug 8, 2025 | clinicaltrials |
| NCT05286229 | A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan | active not recruiting | Phase 1 | 8 | AbbVieINDUSTRY | 1 | Aug 8, 2025 | clinicaltrials |
| NCT02899052 | Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM) | active not recruiting | Phase 2 | 120 | AbbVieINDUSTRY | 5 | Aug 5, 2025 | clinicaltrials |
| NCT05860036 | A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma | active not recruiting | Phase 2 | 40 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT07101913 | Occurrence of Acute Kidney Injury After CAR-T Cells Treatments in B-cell Lymphoma.(AKI CAR) | active not recruiting | — | 300 | Hospices Civils de LyonOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT06944119 | Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia | active not recruiting | — | 250 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jul 28, 2025 | clinicaltrials |
| NCT07088783 | Mobile App Education Based on Orem's Self-Care Model in Multiple Myeloma Patients(OCARE-MM) | active not recruiting | N/A | 60 | OzlemOTHER | 1 | Jul 28, 2025 | clinicaltrials |
| NCT04052880 | Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM | active not recruiting | Phase 2 | 17 | Larysa SanchezOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT04159779 | A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in Greece | active not recruiting | — | 180 | AbbVieINDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT06220097 | Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies | active not recruiting | Phase 2 | 28 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT05123131 | Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma(Isa-RVD) | active not recruiting | Phase 2 | 54 | Cancer Trials IrelandNETWORK | 2 | Jul 8, 2025 | clinicaltrials |
| NCT03421132 | Multiple Myeloma Molecular Monitoring Study(M4) | active not recruiting | — | 96 | Horizon Health NetworkOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT06024694 | Primary Mediastinal Large B-cell Lymphoma With CNS Involvement | active not recruiting | — | 45 | IRCCS San RaffaeleOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT03190525 | Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma(CLARITY) | active not recruiting | — | 530 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 2 | Jun 12, 2025 | clinicaltrials |
| NCT06742879 | A Multi-center Clinical Study of Zanubrutinib in Combination With First-line Chemoimmunotherapy in Patients With Grade 3A High-risk Follicular Lymphoma(ZCM3AHRFL) | active not recruiting | — | 37 | Zhengzhou UniversityOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT03995147 | Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma | active not recruiting | Phase 2 | 51 | University of ChicagoOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06541665 | Phase I Study Evaluating Tolerability, Safety, Pharmacokinetics, and Efficacy of Combined ONO-4059 and R-MPV Therapy for PCNSL | active not recruiting | Phase 1 | 20 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |
| NCT01361711 | Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia | active not recruiting | Phase 2 | 53 | Northwestern UniversityOTHER | 2 | May 23, 2025 | clinicaltrials |
| NCT06552572 | Glofitamab in Relapsed or Refractory Diffuse Large B-cell Lymphoma After CD19 Chimeric Antigen Receptor T-cell Therapy(Glory) | active not recruiting | Phase 2 | 30 | Samsung Medical CenterOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT04460248 | Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL) | active not recruiting | Phase 2 | 40 | Ruijin HospitalOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT03756896 | Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma | active not recruiting | Phase 2 | 29 | Emory UniversityOTHER | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06924424 | Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma | active not recruiting | N/A | 105 | Peking University People's HospitalOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT03600441 | Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma(FORERUNNER) | active not recruiting | Phase 2 | 139 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 3 | Apr 10, 2025 | clinicaltrials |
| NCT03934567 | A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma | active not recruiting | Phase 2 | 87 | Xynomic Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
| NCT04891809 | Isatuximab in Combination With Rd Compared to Rd in Elderly Patients (Aged ≥70 Years) With NDMM | active not recruiting | Phase 2 | 198 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 3 | Apr 10, 2025 | clinicaltrials |
| NCT03376672 | Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients | active not recruiting | Phase 2 | 120 | Raija SilvennoinenOTHER | 4 | Apr 3, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Oct 2, 2025source: clinicaltrials